These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17684485)

  • 1. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
    Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
    Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
    Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
    Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
    Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
    Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
    Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A; Erben P; Ernst T; Mueller MC
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis in chronic myeloid leukemia: when and what to do?
    Branford S; Hughes TP
    Curr Opin Hematol; 2011 Mar; 18(2):111-6. PubMed ID: 21245758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
    Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
    Ou J; Vergilio JA; Bagg A
    Am J Hematol; 2008 Apr; 83(4):296-302. PubMed ID: 17957805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
    Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical studies with imatinib in 2004].
    Eckhardt S
    Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
    J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.